Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men

• Published in: Journal of Atherosclerosis and Thrombosis Vol. 30; no. 7; pp. 767 - 777
• Main Authors: Kunimura, Ayako, Miura, Katsuyuki, Segawa, Hiroyoshi, Torii, Sayuki, Kondo, Keiko, Hisamatsu, Takashi, Kadota, Aya, Fujiyoshi, Akira, Yano, Yuichiro, Nakagawa, Yoshihisa, Okamura, Tomonori, Ueshima, Hirotsugu
• Format: Journal Article
• Language: English; Japanese
• Published: Japan Japan Atherosclerosis Society 01.07.2023
• Subjects: Aged; Aged, 80 and over; Atherosclerosis; Calcium; Cholesterol, LDL; Coronary artery calcium; Coronary Vessels; East Asian People; Humans; Male; Middle Aged; Original; Prevalence; Proprotein Convertase 9; Proprotein convertase subtilisin/kexin type 9; Subtilisins; Coronary artery calcium; Proprotein convertase subtilisin/kexin type 9; Atherosclerosis
• ISSN: 1340-3478; 1880-3873
• DOI: 10.5551/jat.63549

Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population.Methods: Community-dwelling Japanese men (n=622) aged 46–82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60–69, and ≥ 70 years).Results: The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97–1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01–1.88) but not in men aged 60–69 years (aRR 0.96, 95% CI 0.85–1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99–1.19).Conclusions: A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors.